STRATEC Biomedical AG
STRATEC Biomedical AG designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. The company operates through three segments: Instrumentation, Diatron, and Consumables. The Instrumentation segment designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. T… Read more
STRATEC Biomedical AG (SRBZF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.035x
Based on the latest financial reports, STRATEC Biomedical AG (SRBZF) has a cash flow conversion efficiency ratio of 0.035x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($8.05 Million) by net assets ($227.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
STRATEC Biomedical AG - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how STRATEC Biomedical AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
STRATEC Biomedical AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STRATEC Biomedical AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HEINEKEN (HNK1.SG)
STU:HNK1
|
0.045x |
|
Hui Srl
VI:HUI
|
N/A |
|
DKSH Holding Ltd
STU:DS5
|
N/A |
|
Boeing Co
NYSE:BA-PA
|
N/A |
|
Infinitum Copper Corp
OTCQB:INUMF
|
-0.250x |
|
290560
KQ:290560
|
-0.031x |
|
Aspira Womens Health Inc
NASDAQ:AWH
|
0.398x |
|
Tali Digital Ltd
AU:TD1
|
-0.218x |
Annual Cash Flow Conversion Efficiency for STRATEC Biomedical AG (2014–2023)
The table below shows the annual cash flow conversion efficiency of STRATEC Biomedical AG from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $233.33 Million | $19.43 Million | 0.083x | +82.38% |
| 2022-12-31 | $225.18 Million | $10.28 Million | 0.046x | -85.20% |
| 2021-12-31 | $205.76 Million | $63.47 Million | 0.308x | +67.12% |
| 2020-12-31 | $172.54 Million | $31.85 Million | 0.185x | -2.82% |
| 2017-12-31 | $157.84 Million | $29.98 Million | 0.190x | +66.32% |
| 2016-12-31 | $142.34 Million | $16.26 Million | 0.114x | -42.85% |
| 2015-12-31 | $130.28 Million | $26.03 Million | 0.200x | -43.67% |
| 2014-12-31 | $112.05 Million | $39.75 Million | 0.355x | -- |